Biomarker > Asan Preclinical Evaluation center for cancer therapeutiX
List of Models
- Cell lines of various cancer types, panel of biomarker-engineered cell lines, and drug-resistant cell lines
- Animal models implanted with cancer cells of various types, biomarker-engineered cell line xenografts, and genetically engineered mouse models
- Patient-derived primary cells, patient-derived xenograft (PDX) models, and patient samples (tumor tissues, normal tissues, blood) with clinical, genomic, and drug response data
- Toxicity risk assessment models using biomarkers
- Development of new models tailored to client needs
Service
- Customized study design (in vitro, in vivo, ex vivo)
- Biomarker validation and analysis based on therapeutic response
- Biomarker discovery based on clinical needs
- Early diagnosis and validation of prognostic biomarkers
- Evaluation using clinical specimens (blood, tissue) in custom cancer models
- Identification of companion diagnostic biomarkers for therapeutics
- Next generation sequencing-based genomic alterations, copy number variations, and expression levels
- Reverse phase protein array-based protein modifications
- Mechanism of action (MOA) and proof-of-concept (POC) validation
